Navigation Links
Novel Compound Shows Promise for Treatment of Alcoholism
Date:9/11/2008

BIRMINGHAM, Ala., Sept. 11 /PRNewswire-USNewswire/ --- Southern Research Institute and Gallo Research Center today announced that peer-reviewed results from a study testing Naltrexone-derived pyridomorphinan (SoRI-9409) will be published in the December 2008 issue of the journal Biological Psychiatry. The publication is available online today at the journal's website, and suggests that a new compound that causes selective and long-lasting reduction in ethanol consumption might be a promising candidate as a novel treatment for alcoholism.

The article, "A Novel Delta Opioid Receptor Antagonist, SoRI-9409, Produces a Selective and Long-Lasting Decrease in Ethanol Consumption in Heavy-Drinking Rats" by Selena Bartlett, BPharm PhD, Director of Preclinical Development Group at the Gallo Research Center at University of California San Francisco, et al presents the effects of SoRI-9409 on ethanol consumption. These are promising developments for the treatment of alcoholism. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) estimates 15.1 million people are alcohol-abusing or alcohol-dependent individuals. There are currently only three FDA-approved options for the treatment of alcoholism.

The compound, SoRI-9409, was first designed and synthesized in Southern Research's Drug Discovery research division by Dr. Subramaniam (Sam) Ananthan under U.S. Government Grant DA008883. "Southern Research has been particularly interested in ligands that interact with opioid delta receptor subtype since such ligands hold promise as therapeutic agents for treatment of drug addictions and other disorders," said Dr. Ananthan, senior scientist and manager of Computational Chemistry and CNS Discovery Chemistry at Southern Research Institute. "The present findings by Dr. Bartlett and her group on the effect of SoRI-9409 on its ability to reduce alcohol intake not only provides us with a new drug lead, but also serves as the impetus for further research aimed at
'/>"/>

SOURCE Southern Research Institute
Copyright©2008 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
2. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
3. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
4. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
7. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
8. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),...overing,developingandcommercializingnoveldrugstotr...iscalyearendedSeptember30,2009.AtSeptember30,2009P...shortterminvestments. ,, PipelineUpdateand2009...,, InlateNovember2009,anindependentDataMonitori...
(Date:11/25/2009)...PRNewswire-FirstCall/--Formanyofthemillionsofheari...thuntreated hearingloss ,theholidaysmaynotbealltha...eniorvicepresidentofHearUSA(Amex: EAR ),oneofAmeri...idstudieshavelinkedhearinglosstostress,frustration...holidaygatheringswithfamiliesandfriends,whenmanyof...
(Date:11/25/2009)...--Reportlinker.comannouncesthatanewmarketresearchr...sDentalDevicesMarketAnalysisandForecaststo2015 ,...tates-Dental-Devices-Market-Analysis-and-Forecasts...etAnalysisandForecaststo2015 ,, Summary ,,...onanddatarelatingtotheUSdentaldevicesmarket.Italso...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Elsevier Announces 2008 Journal Impact Factor Highlights 50255 1Elsevier Announces 2008 Journal Impact Factor Highlights 50255 2Elsevier Announces 2008 Journal Impact Factor Highlights 50255 3Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 1Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 2Medicsight Launches ColonCAD 28TM 29 Online CTC Platform 50253 3Biostar Pharmaceuticals Inc Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base 50251 1Biostar Pharmaceuticals Inc Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base 50251 2Biostar Pharmaceuticals Inc Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base 50251 3
...007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) tod...tudy of Proellex in the treatment of,endometriosis...menopausal women and has completed six months of d...ellex(TM) as well as a,positive control arm. The p... known as Lupron(R) or leuprolide acetate, commonl...
...- Accera, Inc.,today is presenting data from an op... of AC-1202 (Ketasyn) in Alzheimer,s disease (AD),...ference on,Prevention of Dementia in Washington, D...al and preclinical studies, AC-1202 was,shown to b...,cognition of subjects of a particular pharmacogen...
Other Medicine Technology:Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 2Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 3Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 4Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 5Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 6Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4
(Date:11/26/2009)... Research Triangle Dental (RTDental), a leadin... today announced the expansion of its services to ... Dr. Doug Macmillan. , ... pleased to announce that Dr. Doug Macmillan, an e... an additional advanced training seminar. RTDenta...
(Date:11/25/2009)...lif.,Nov.25/PRNewswire-FirstCall/-- OnyxPharmaceu...panywillhosttwoinvestoreventsinDecember: ,, A...00a.m.ET ,, Principalinvestigatorswilldiscuss...nd/orrefractorymultiplemyeloma,asfeaturedatthe51st...positioninNewOrleans,LA.Theteleconferencewillbegin...
(Date:11/25/2009)...v.25/PRNewswire-USNewswire/--TheBlackAIDSInstitute...cutiveleadershipfor2010. ,, ThenewBoardMembersa...licpolicy,law,finance,governmenthealthprograms,edi...esfromawiderangeofpersonalbackgroundsincludingboth...IVthemselves,andrepresentingmultipleagegroups. ,...
(Date:11/25/2009)...overy that grew out of a collaboration between UCL... hope to the nearly 10 million Americans who suffe...nown as hardening of the arteries, peripheral arte...lem in which narrowed arteries reduce blood flow t...g for vascular disease, heart attack and stroke, a...
(Date:11/25/2009)...s could lead mothers to overlook needed care, stud...y News) -- A mother,s depression can worsen her ch...eir six-month study of 262 black mothers and their...re depressive symptoms had more frequent asthma sy...ssive symptoms had less frequent asthma symptoms. ...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Mom's Depression May Worsen Child's Asthma 2
...co, Inc. is,pleased to announce the introduction o...rapid point of care system utilizes a chemilumines...separation method that allows,this system to repor...ole blood sample., The PATHFAST system can handle...
..., Inc.,(the "Company") (Nasdaq: AFAM ) announced ...public offering price of $17.75 per share. In conn...as been granted an option to,purchase up to 337,50...fering, after underwriting discounts,and estimated...
...heterogeneous group and may not always be associat...he study of 145 triple negative breast cancers (i....gesterone receptor-negative and HER2-negative) in ...of the study. , Triple negative breast cancer i...
...l can detect prostate cancer and provide undistort...te tumor localization, according to a recent study...ersity in Columbus, OH. , The 3T MRI datasets we... an endorectal coil leads to deformation of the pr...
...confirming large bowel obstruction and identifying... recent study conducted by researchers at the Univ...There is very little published evidence regarding ...n clinical problem and plain films have been shown...
...h 3T MR-guided focused ultrasound (MRgFUS) is safe...t study conducted by researchers at Weill Cornell ...25% of women in the United States have clinically ...n developed in radiology, includingnon-invasive MR...
Other Medicine News:Health News:Almost Family Announces Pricing of 2,250,000 Common Shares 2Health News:CT useful and effective when diagnosing patients with large bowel obstruction 2
Lorenz 2.0 mm Flexible Titanium
Craniofix Titanium Clamp
...e Cfix cable fixation system is a flexible titaniu...crimping and address the surgeon's need for intrao... provides the surgeon with the ability to retighte...tting without the need for additional cables. Quic...
Grafton DBM Crunch
Medicine Products: